Table 2.

Sensitivity analyses of overall survival and time to tumor progression between standard-dose and low-dose groups after IPTW adjustment.

Sensitivity Analyses	Overall Survival (HR, 95% CI)	Time to Tumor Progression (HR, 95% CI)
Pembrolizumab ≥ 2 mg/kg as standard group †	0.84 (0.62–1.14)	0.85 (0.68–1.05)
Pembrolizumab ≥ 1.9 mg/kg as standard group †	0.78 (0.58–1.03)	0.85 (0.69–1.06)
Pembrolizumab ≥ 1.8 mg/kg as standard group †	0.73 (0.55–0.97) *	0.81 (0.66–1.01)
Propensity score matching cohort (pembrolizumab ≥2 mg/kg as standard group)	0.83 (0.52–1.34)	0.86 (0.61–1.20)

Abbreviations—HR: hazard ratio, CI: confidence interval: Note: ^† adjusted by inverse probability of treatment weighting; * p < 0.05; Propensity score model covariates include: age, sex, Eastern Cooperative Oncology Group, alcohol habit, smoking habit, line of pembrolizumab, concomitant chemotherapy, Charlson comorbidity index, histologic features, metastasis status, programmed death-ligand 1 tumor proportion score and chronic diseases.